Mark Adams, Ph.D.

Professor and Deputy Director, JAX Genomic Medicine

Leads the research and clinical genome sequencing groups.

As one of the founding scientists at TIGR, Dr. Adams contributed extensively to the first genome sequence of a free-living organism, Haemophilus influenzae, and other microbial genomes. A co-founder of Celera Genomics, he led the DNA sequencing and genome annotation groups. He directed the Drosophila, human, and mouse genome sequencing projects, and a large-scale re-sequencing program to identify novel SNPs in humans.

From 2003-2011, Dr. Adams was Associate Professor of Genetics at Case Western Reserve University where he developed a research program in the evolution and mechanisms of antibiotic resistance in the nosocomial pathogen Acinetobacter baumannii. He also served as Director of the Genomics Core facility.

From 2011-2016, Dr. Adams was the Scientific Director and Professor at the J. Craig Venter Institute. There he directed programs that characterized genomic changes in the evolution of antibiotic resistance in hospital-acquired infections.

Dr. Adams joined The Jackson Laboratory for Genomic Medicine in 2016, initially as director of Microbial Genomic Services. In 2020, he transitioned to lead a new R&D group for JAX’s clinical diagnostic laboratory. In 2023, he became the director of the Genome Technologies Scientific Service and leader of the CLIA-certified and CAP-accredited Advanced Precision Medicine Laboratory. Dr. Adams also serves as the deputy director for JAX Genomic Medicine.

He received a B.A. in Chemistry from Warren Wilson College in Swannanoa, NC and a Ph.D. in Biological Chemistry from the University of Michigan.

Mark Adams on ORCID